Advertisement
Original Article| Volume 52, P54-59, June 2018

Risk factors for the development of incident atrial fibrillation in patients with cardiac implantable electronic devices

  • Kazuo Miyazawa
    Correspondence
    Corresponding author at: University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, England, United Kingdom.
    Affiliations
    Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom

    Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
    Search for articles by this author
  • Yusuke Kondo
    Affiliations
    Department of Advanced Cardiovascular Therapeutics, Chiba University Graduate School of Medicine, Chiba, Japan
    Search for articles by this author
  • Miyo Nakano
    Affiliations
    Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
    Search for articles by this author
  • María Asunción Esteve-Pastor
    Affiliations
    Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom

    Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, Murcia, Spain
    Search for articles by this author
  • José Miguel Rivera-Caravaca
    Affiliations
    Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom

    Department of Hematology and Clinical Oncology, Hospital General Universitario Morales Meseguer, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain
    Search for articles by this author
  • Keitaro Senoo
    Affiliations
    Department of Advanced Cardiovascular Therapeutics, Chiba University Graduate School of Medicine, Chiba, Japan

    Department of Arrhythmia, Koseika Takeda Hospital, Kyoto, Japan
    Search for articles by this author
  • Yoshio Kobayashi
    Affiliations
    Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
    Search for articles by this author
  • Gregory Y.H. Lip
    Affiliations
    Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom

    Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
    Search for articles by this author
Published:February 26, 2018DOI:https://doi.org/10.1016/j.ejim.2018.02.019

      Highlights

      • New-onset AF was detected in 21% of patients with CIEDs.
      • Age, diabetes mellitus, heart failure, and left atrial enlargement predicted new-onset AF.
      • Four clinical factors provide clinically useful risk assessment of new-onset AF.

      Abstract

      Introduction

      Cardiac implantable electronic devices (CIEDs) can detect atrial fibrillation (AF) early and accurately. Risk factors for the development of new-onset AF in patients with CIEDs remains uncertain.

      Methods

      Patients with CIEDs who visited Chiba University Hospital between January 2016 and December 2016 were enrolled. We only included patients without single chamber CIEDs or a known history of AF.

      Results

      Of 371 patients with CIEDs, 78 (21.0%; median age 61.0 years, 65.5% male) developed new-onset AF. Multivariate analysis demonstrated that independent predictors for the development of new or incident AF were age ≥65 years (odd ratio [OR] 2.76, 95% confidence interval [CI] 1.54–4.96, P = 0.001), diabetes mellitus (OR 2.24, 95% CI 1.20–4.19, P = 0.011), congestive heart failure (OR 1.94, 95% CI 1.06–3.54, P = 0.031), and left atrial volume index >34 ml/m2 (OR 3.51, 95% CI 1.96–6.25, P < 0.001). Based on these 4 clinical factors (age ≥ 65, diabetes mellitus, congestive heart failure, left atrial volume index > 34 ml/m2) there was a good predictive ability for new AF development (AUC 0.728) and clinically usefulness using decision curve analysis.

      Conclusions

      A substantial number of patients with CIEDs develop new-onset AF. Four clinical factors (age ≥ 65, diabetes mellitus, congestive heart failure, left atrial volume index > 34 ml/m2) independently predicted new-onset AF and may provide an approach to clinically useful risk assessment for incident AF.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vermond R.A.
        • Geelhoed B.
        • Verweij N.
        • Tieleman R.G.
        • Van der Harst P.
        • Hillege H.L.
        • et al.
        Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: a community-based study from the Netherlands.
        J Am Coll Cardiol. 2015; 66: 1000-1007
        • Savelieva I.
        • Camm A.J.
        Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management.
        J Interv Card Electrophysiol. 2000; 4: 369-382
        • Gladstone D.J.
        • Spring M.
        • Dorian P.
        • Panzov V.
        • Thorpe K.E.
        • Hall J.
        • et al.
        Atrial fibrillation in patients with cryptogenic stroke.
        N Engl J Med. 2014; 370: 2467-2477
        • Lin H.J.
        • Wolf P.A.
        • Benjamin E.J.
        • Belanger A.J.
        • D'Agostino R.B.
        Newly diagnosed atrial fibrillation and acute stroke. The Framingham Study.
        Stroke. 1995; 26: 1527-1530
        • Pollak W.M.
        • Simmons J.D.
        • Interian Jr., A.
        • Atapattu S.A.
        • Castellanos A.
        • Myerburg R.J.
        • et al.
        Clinical utility of intraatrial pacemaker stored electrograms to diagnose atrial fibrillation and flutter.
        Pacing Clin Electrophysiol. 2001; 24: 424-429
        • Glotzer T.V.
        • Hellkamp A.S.
        • Zimmerman J.
        • Sweeney M.O.
        • Yee R.
        • Marinchak R.
        • et al.
        Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST).
        Circulation. 2003; 107: 1614-1619
        • Glotzer T.V.
        • Daoud E.G.
        • Wyse D.G.
        • Singer D.E.
        • Ezekowitz M.D.
        • Hilker C.
        • et al.
        The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study.
        Circ Arrhythm Electrophysiol. 2009; 2: 474-480
        • Healey J.S.
        • Connolly S.J.
        • Gold M.R.
        • Israel C.W.
        • Van Gelder I.C.
        • Capucci A.
        • et al.
        Subclinical atrial fibrillation and the risk of stroke.
        N Engl J Med. 2012; 366: 120-129
        • Pritchett A.M.
        • Jacobsen S.J.
        • Mahoney D.W.
        • Rodeheffer R.J.
        • Bailey K.R.
        • Redfield M.M.
        Left atrial volume as an index of left atrial size: a population-based study.
        J Am Coll Cardiol. 2003; 41: 1036-1043
        • Kirchhof P.
        • Benussi S.
        • Kotecha D.
        • Ahlsson A.
        • Atar D.
        • Casadei B.
        • et al.
        2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Eur Heart J. 2016; 37: 2893-2962
        • Gage B.F.
        • Waterman A.D.
        • Shannon W.
        • Boechler M.
        • Rich M.W.
        • Radford M.J.
        Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.
        JAMA. 2001; 285: 2864-2870
        • Lip G.Y.
        • Nieuwlaat R.
        • Pisters R.
        • Lane D.A.
        • Crijns H.J.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.
        Chest. 2010; 137: 263-272
        • de Vos C.B.
        • Pisters R.
        • Nieuwlaat R.
        • Prins M.H.
        • Tieleman R.G.
        • Coelen R.J.
        • et al.
        Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis.
        J Am Coll Cardiol. 2010; 55: 725-731
        • Suenari K.
        • Chao T.F.
        • Liu C.J.
        • Kihara Y.
        • Chen T.J.
        • Chen S.A.
        Usefulness of HATCH score in the prediction of new-onset atrial fibrillation for Asians.
        Medicine (Baltimore). 2017; 96e5597
        • DeLong E.R.
        • DeLong D.M.
        • Clarke-Pearson D.L.
        Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.
        Biometrics. 1988; 44: 837-845
        • Vickers A.J.
        • Elkin E.B.
        Decision curve analysis: a novel method for evaluating prediction models.
        Med Decis Making. 2006; 26: 565-574
        • Botto G.L.
        • Padeletti L.
        • Santini M.
        • Capucci A.
        • Gulizia M.
        • Zolezzi F.
        • et al.
        Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events.
        J Cardiovasc Electrophysiol. 2009; 20: 241-248
        • Capucci A.
        • Santini M.
        • Padeletti L.
        • Gulizia M.
        • Botto G.
        • Boriani G.
        • et al.
        Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers.
        J Am Coll Cardiol. 2005; 46: 1913-1920
        • Gillis A.M.
        • Morck M.
        Atrial fibrillation after DDDR pacemaker implantation.
        J Cardiovasc Electrophysiol. 2002; 13: 542-547
        • Healey J.S.
        • Martin J.L.
        • Duncan A.
        • Connolly S.J.
        • Ha A.H.
        • Morillo C.A.
        • et al.
        Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation.
        Can J Cardiol. 2013; 29: 224-228
        • Swiryn S.
        • Orlov M.V.
        • Benditt D.G.
        • DiMarco J.P.
        • Lloyd-Jones D.M.
        • Karst E.
        • et al.
        Clinical implications of brief device-detected atrial tachyarrhythmias in a cardiac rhythm management device population: results from the registry of atrial tachycardia and atrial fibrillation episodes.
        Circulation. 2016; 134: 1130-1140
        • Kim B.S.
        • Chun K.J.
        • Hwang J.K.
        • Park S.J.
        • Park K.M.
        • Kim J.S.
        • et al.
        Predictors and long-term clinical outcomes of newly developed atrial fibrillation in patients with cardiac implantable electronic devices.
        Medicine (Baltimore). 2016; 95e4181
        • Ogino Y.
        • Ishikawa T.
        • Ishigami T.
        • Matsumoto K.
        • Hosoda J.
        • Iguchi K.
        • et al.
        Characteristics and prognosis of pacemaker-identified new-onset atrial fibrillation in Japanese people.
        Circ J. 2017; 81: 794-798
        • Sweeney M.O.
        • Hellkamp A.S.
        • Ellenbogen K.A.
        • Greenspon A.J.
        • Freedman R.A.
        • Lee K.L.
        • et al.
        Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction.
        Circulation. 2003; 107: 2932-2937
        • Quesada A.
        • Botto G.
        • Erdogan A.
        • Kozak M.
        • Lercher P.
        • Nielsen J.C.
        • et al.
        Managed ventricular pacing vs. conventional dual-chamber pacing for elective replacements: the PreFER MVP study: clinical background, rationale, and design.
        Europace. 2008; 10: 321-326
        • Kannel W.B.
        • Abbott R.D.
        • Savage D.D.
        • McNamara P.M.
        Coronary heart disease and atrial fibrillation: the Framingham Study.
        Am Heart J. 1983; 106: 389-396
        • Psaty B.M.
        • Manolio T.A.
        • Kuller L.H.
        • Kronmal R.A.
        • Cushman M.
        • Fried L.P.
        • et al.
        Incidence of and risk factors for atrial fibrillation in older adults.
        Circulation. 1997; 96: 2455-2461
        • Samol A.
        • Masin M.
        • Gellner R.
        • Otte B.
        • Pavenstadt H.J.
        • Ringelstein E.B.
        • et al.
        Prevalence of unknown atrial fibrillation in patients with risk factors.
        Europace. 2013; 15: 657-662
        • Wiesel J.
        • Arbesfeld B.
        • Schechter D.
        Comparison of the microlife blood pressure monitor with the Omron blood pressure monitor for detecting atrial fibrillation.
        Am J Cardiol. 2014; 114: 1046-1048
        • Kearley K.
        • Selwood M.
        • Van den Bruel A.
        • Thompson M.
        • Mant D.
        • Hobbs F.R.
        • et al.
        Triage tests for identifying atrial fibrillation in primary care: a diagnostic accuracy study comparing single-lead ECG and modified BP monitors.
        BMJ Open. 2014; 4: e004565
        • McManus D.D.
        • Lee J.
        • Maitas O.
        • Esa N.
        • Pidikiti R.
        • Carlucci A.
        • et al.
        A novel application for the detection of an irregular pulse using an iPhone 4S in patients with atrial fibrillation.
        Heart Rhythm. 2013; 10: 315-319
        • Benjamin E.J.
        • Levy D.
        • Vaziri S.M.
        • D'Agostino R.B.
        • Belanger A.J.
        • Wolf P.A.
        Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.
        JAMA. 1994; 271: 840-844
        • Qureshi W.
        • Soliman E.Z.
        • Solomon S.D.
        • Alonso A.
        • Arking D.E.
        • Shah A.
        • et al.
        Risk factors for atrial fibrillation in patients with normal versus dilated left atrium (from the Atherosclerosis Risk in Communities Study).
        Am J Cardiol. 2014; 114: 1368-1372
        • Li Y.
        • Ding W.
        • Wang H.
        • Song N.
        • Lin L.
        • Wang Z.
        • et al.
        Relationship of CHA2DS2-VASc and CHADS2 score to left atrial remodeling detected by velocity vector imaging in patients with atrial fibrillation.
        PLoS One. 2013; 8e77653
        • Chao T.F.
        • Lin Y.J.
        • Tsao H.M.
        • Tsai C.F.
        • Lin W.S.
        • Chang S.L.
        • et al.
        CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation.
        J Am Coll Cardiol. 2011; 58: 2380-2385
        • Saliba W.
        • Gronich N.
        • Barnett-Griness O.
        • Rennert G.
        Usefulness of CHADS2 and CHA2DS2-VASc scores in the prediction of new-onset atrial fibrillation: a population-based study.
        Am J Med. 2016; 129: 843-849